C5a-C5aR1 induces endoplasmic reticulum stress to accelerate vascular calcification via PERK-eIF2α-ATF4-CREB3L1 pathway
Authors:
Open Access
- 21 August 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 119 (15) , 2563-2578
Abstract
Vascular calcification (VC) predicts the morbidity and mortality in cardiovascular diseases. Vascular smooth muscle cells (VSMCs) osteogenic transdifferentiation is the crucial pathological basis for VC. To date, the molecular pathogenesis is still largely unclear. Notably, C5a-C5aR1 contributes to the development of cardiovascular diseases, and it’s closely related to physiological bone mineralization which is similar to VSMCs osteogenic transdifferentiation. However, the role and underlying mechanisms of C5a-C5aR1 in VC remain unexplored. A cross-sectional clinical study was utilized to examine the association between C5a and VC. Chronic kidney diseases mice and calcifying VSMCs models were established to investigate the effect of C5a-C5aR1 in VC, evaluated by changes in calcium deposition and osteogenic markers. The cross-sectional study identified that high level of C5a was associated with increased risk of VC. C5a dose-responsively accelerated VSMCs osteogenic transdifferentiation accompanying with increased the expression of C5aR1. Meanwhile, the antagonists of C5aR1, PMX 53, reduced calcium deposition and osteogenic transdifferentiation both in vivo and in vitro. Mechanistically, C5a-C5aR1 induced endoplasmic reticulum stress and then activated PERK-eIF2α-ATF4 pathway to accelerated VSMCs osteogenic transdifferentiation. In addition, cAMP-response element-binding protein 3-like 1 (CREB3L1) was a key downstream mediator of PERK-eIF2α-ATF4 pathway which accelerated VSMCs osteogenic transdifferentiation by promoting the expression of COL1α1. High level of C5a was associated with increased risk of VC, and it accelerated VC by activating the receptor C5aR1. PERK-eIF2α-ATF4-CREB3L1 pathway of endoplasmic reticulum stress was activated by C5a-C5aR1, hence promoting VSMCs osteogenic transdifferentiation. Targeting C5 or C5aR1 may be an appealing therapeutic target for VC.Keywords
Funding Information
- National key research and development program (2020YFC2004405)
- National Natural Science Foundation (82073408, 82270771, 82061160372, and 81870506)
- Regional Joint Funding Key Project of Guangdong Basic Research
- Basic Research for Application (2021B1515120083)
- Basic Research Project of Shenzhen Science
- Technology Innovation Committee (JCYJ20180306174648342, JCYJ20190808102005602, and KCXFZ20211020163801002)
- Shenzhen Key Medical Discipline Construction Fund (SZXK002)
- Guangdong Basic and Applied Basic Research Foundation (2020B1515120037)
This publication has 56 references indexed in Scilit:
- PERK‐eIF2α‐ATF4‐CHOP Signaling Contributes to TNFα‐Induced Vascular CalcificationJournal of the American Heart Association, 2013
- Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysmProceedings of the National Academy of Sciences, 2012
- C5aR‐antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healingJournal of Orthopaedic Research, 2011
- Arterial Calcification in Chronic Kidney Disease: Key Roles for Calcium and PhosphateCirculation Research, 2011
- Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL‐1βJournal of Cellular Biochemistry, 2011
- C5a Receptor Targeting in Neointima Formation After Arterial Injury in Atherosclerosis-Prone MiceCirculation, 2010
- Coronary Artery Calcium Score and Risk Classification for Coronary Heart Disease PredictionJAMA, 2010
- Signalling mediated by the endoplasmic reticulum stress transducer OASIS is involved in bone formationNature Cell Biology, 2009
- Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: Potential mechanism for uremic vascular calcificationKidney International, 2008
- Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosisEuropean Heart Journal, 2005